131 related articles for article (PubMed ID: 35195779)
1. DNA methylation marker to estimate ovarian cancer cell fraction.
Ebata T; Yamashita S; Takeshima H; Yoshida H; Kawata Y; Kino N; Yasugi T; Terao Y; Yonemori K; Kato T; Ushijima T
Med Oncol; 2022 Feb; 39(5):78. PubMed ID: 35195779
[TBL] [Abstract][Full Text] [Related]
2. Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.
Sánchez-Vega F; Gotea V; Petrykowska HM; Margolin G; Krivak TC; DeLoia JA; Bell DW; Elnitski L
Epigenetics; 2013 Dec; 8(12):1355-72. PubMed ID: 24149212
[TBL] [Abstract][Full Text] [Related]
3. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
[TBL] [Abstract][Full Text] [Related]
4. Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients.
Miller BF; Petrykowska HM; Elnitski L
Sci Rep; 2021 Jan; 11(1):221. PubMed ID: 33420235
[TBL] [Abstract][Full Text] [Related]
5. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation marker to estimate the breast cancer cell fraction in DNA samples.
Ishihara H; Yamashita S; Fujii S; Tanabe K; Mukai H; Ushijima T
Med Oncol; 2018 Sep; 35(11):147. PubMed ID: 30218172
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Cancer Cell Fraction Estimation in a DNA Sample.
Ishihara H; Yamashita S; Amano R; Kimura K; Hirakawa K; Ueda T; Murakami Y; Tamori A; Tanabe K; Kawada N; Hagihara A; Ushijima T
Oncology; 2018; 95(6):370-379. PubMed ID: 30149376
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
Herzog C; Jones A; Evans I; Reisel D; Olaitan A; Doufekas K; MacDonald N; Rådestad AF; Gemzell-Danielsson K; Zikan M; Cibula D; Dostálek L; Paprotka T; Leimbach A; Schmitt M; Ryan A; Gentry-Maharaj A; Apostolidou S; Rosenthal AN; Menon U; Widschwendter M
Int J Cancer; 2024 Feb; 154(4):679-691. PubMed ID: 37861205
[TBL] [Abstract][Full Text] [Related]
9. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
[TBL] [Abstract][Full Text] [Related]
10. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
11. Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer.
Wiesmueller F; Kopke J; Aust D; Roy J; Dahl A; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683647
[TBL] [Abstract][Full Text] [Related]
12. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
13. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract][Full Text] [Related]
14. Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development.
Margolin G; Petrykowska HM; Jameel N; Bell DW; Young AC; Elnitski L
J Mol Diagn; 2016 Mar; 18(2):283-98. PubMed ID: 26857064
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the fraction of cancer cells in a tumor DNA sample using DNA methylation.
Takahashi T; Matsuda Y; Yamashita S; Hattori N; Kushima R; Lee YC; Igaki H; Tachimori Y; Nagino M; Ushijima T
PLoS One; 2013; 8(12):e82302. PubMed ID: 24312652
[TBL] [Abstract][Full Text] [Related]
17. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Verma M; Ebina Y; Nomura E; Yamamoto R; Sakuragi N; Dahiya R
Biochem Biophys Res Commun; 2004 Apr; 316(4):1156-62. PubMed ID: 15044106
[TBL] [Abstract][Full Text] [Related]
18. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
19. [Genome-wide analysis of DNA methylation in prostate cancer using the technology of Infinium HumanMethylation450 BeadChip (HM450)].
Babalyan KA; Sultanov R; Generozov EV; Zakharzhevskaya NB; Sharova EI; Peshkov MN; Vasilev AO; Govorov AV; Pushkar DY; Prilepskaya EA; Danilenko SA; Babikova EA; Larin AK; Govorun VM
Vopr Onkol; 2016; 62(1):122-32. PubMed ID: 30444590
[TBL] [Abstract][Full Text] [Related]
20. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
